Co-Diagnostics (CODX) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was $641,141, down from $2,457,098 in Q3 2023, mainly due to lower grant revenue and product sales.

• Net loss for Q3 2024 increased to $9,696,455 ($0.32 per share) from $5,982,194 ($0.20 per share) in Q3 2023, driven by reduced grant revenue and changes in fair value of acquisition contingencies.

• Advanced development of a portable, low-cost PCR platform and associated test pipeline, including COVID-19, TB, respiratory multiplex, HPV multiplex, and Strep A tests, with FDA 510(k) and EUA applications under review.

• Focused on expanding regulatory submissions and commercialization in international markets such as India, Africa, Central and South America, and the Middle East.

• Progressed manufacturing capacity with facility expansion in India and continued domestic production.

Financial highlights

• Q3 2024 product revenue: $206,876; grant revenue: $434,265; total revenue: $641,141.

• Gross profit for Q3 2024 was $343,738, with cost of revenue at $297,403.

• Operating expenses for Q3 2024 were $10,578,675, down from $11,137,277 in Q3 2023.

• Adjusted EBITDA loss was $8,800,000 for the quarter.

• Cash, cash equivalents, and marketable securities totaled $37,662,201 as of September 30, 2024.

Outlook and guidance

• Management expects existing capital resources and future sales to meet operating requirements for the next 12 months, but anticipates continued operating losses and cash use in the near term.

• Preparing for clinical trials and regulatory submissions for TB and HPV tests in India and Africa in early 2025.

• Oligonucleotide manufacturing facility in India set for inauguration in early December 2024.

• Focused on maintaining a healthy balance sheet and managing expenses to support long-term growth.

• Optimistic about 2025 and future pipeline developments.